All Activity

Thank you very much for this useful article. I like it. แทงบอลสด

Congressional researchers are detailing options for how lawmakers could respond to a recent Supreme Court decision to uphold the gun rights of people who use marijuana. Last month, the nine justices unanimously ruled that the government’s efforts to criminalize possession of firearms for cannabis consumers through a statute known as 922(g)(3) is an unconstitutional violation of the Second Amendment. The court itself described its ruling as “narrow,” and the new Congressional Research Service (CRS) report on the issue said it “explicitly recognized room for legislative action in this area.” The court’s opinion in the case, U.S. vs. Hemani, does not address “efforts to ban addicts, or those presently intoxicated, from possessing a firearm,” the majority opinion says. “We do not address other prophylactic laws Congress might adopt after determining that users of a particular drug pose a special risk of misusing firearms.” “We do not even address whether the government could bring a prosecution under §922(g)(3) accompanied by individualized proof that the defendant’s use of marijuana (or any other drug) renders him a danger to himself or others,” it said. “Or proof that a certain drug always renders its users dangerous because of its potency or for some other reason.” The new CRS report says that “Congress may accept this invitation to amend § 922(g)(3) if it chooses.” “For example, Congress might opt to amend the law to more narrowly capture only those individuals who may, because of their use or the nature of the drug involved, present a danger to themselves or others,” it says. “Congress may be interested in modifying other categorical prohibitions in § 922(g) in light of the Court’s discussion of historical laws, particularly to the extent that the government may turn to these laws in future cases to defend the constitutionality of a modern firearms restriction.” The report from congressional researchers also says, however, that lawmakers may alternatively want to “allow lower courts to sort out any residual questions from Hemani,” including how to interpret whether language in the statute that bars people who are “addicted to” illegal drugs from possessing firearms is consistent with the Second Amendment. “A number of petitions for review raising Second Amendment issues have been filed with the Court,” CRS said. “Should the Court grant any such petitions, Congress may have more information to consider when determining whether and what adjustments to § 922(g) may be appropriate.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — The Supreme Court, for its part, has already started applying its finding in the case to those involving other cannabis consumers who were prosecuted for possessing firearms. A recent poll, meanwhile, found that most Americans support the Supreme Court’s decision on gun rights for cannabis consumers—including majorities across party lines. Also, a federal agency that regulates guns says it is planning to provide guidance in the wake of the court ruling on the Second Amendment rights of people who use marijuana. The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) noted the court’s unanimous ruling in a social media post, saying it is “reviewing the decision and assessing its impact.” “Additional guidance will be provided soon,” the agency said. ATF is responsible for carrying out the federal law known as 922(g)(3) that prohibits people who illegally consume controlled substances from possessing or purchasing firearms and has now been partially struck down when it comes to cannabis consumers who otherwise show no signs of posing a threat of violence. The court, in the majority opinion, said that the broad ban and the government’s effort to defend it are “at odds with” the Trump administration’s move to federally reschedule cannabis. The government “asks us to conclude that anyone who regularly uses marijuana is categorically violent and dangerous without any further showing,” the opinion says. “All based on little more than its current say-so, one at odds with its own regulatory actions. And affording the government that kind of ‘broad power to designate any group as dangerous and thereby disqualify its members from having a gun’ would risk allowing it to ‘quickly swallow’ the Second Amendment.” ATF in May posted a proposed revised version of Form 4473, which must be filled out by anyone purchasing a gun from a federally licensed firearms dealer, to acknowledge the federally legal status of medical marijuana under the Trump administration’s recent move to reschedule the drug. The change is likely due to the fact that in April, Acting Attorney General Todd Blanche issued an order that immediately moved marijuana products regulated by a state medical cannabis license to Schedule III of the Controlled Substances Act (CSA), and similarly rescheduled marijuana products that are approved by the Food and Drug Administration (FDA). A hearing to consider broader cannabis rescheduling is scheduled for this month. Advocates expect that ATF will need to issue further changes to the gun purchase form in the wake of the court’s ruling in U.S. v. Hemani, the case it decided this month. ATF also moved earlier this year to loosen rules that bar people who consume marijuana and other illegal drugs from being able to lawfully purchase and possess guns by making it so fewer people would be affected. The interim final rule from ATF, which is currently open for public comment through June 30, seeks to update the definition of “unlawful user of or addicted to any controlled substance” under an existing policy that has been interpreted to deny Second Amendment rights to people who have used illegal substances a single time within the past year. The Supreme Court heard arguments in the Hemani case in March, with the Trump administration urging the justices to uphold the ban on gun possession by marijuana users. The federal government has consistently maintained its position that the law appropriately disarms marijuana users who, they claim, are uniquely dangerous. To meet a strict Supreme Court standard for firearm laws, the Department of Justice has also drawn sometimes eyebrow-raising comparisons between cannabis consumers and the mentally ill and habitual drunkards to establish a historical analogue that aligns with the country’s founding era. “Those laws, the government contends, demonstrate a tradition of firearm regulation consistent with its effort to disarm any regular user of any controlled substance without any further showing. But the government’s analogy fails under every measure it asks us to consider,” the court’s opinion said. “The historical laws on which it relies targeted different kinds of people, did so for different reasons, and operated in different ways. And faced with all these shortcomings in the government’s submission, we cannot say it has carried its conceded burden of showing its prosecution of Mr. Hemani complies with the Second Amendment.” Trump administration Solicitor General D. John Sauer, for his part, told the Supreme Court in a brief that people who use illegal drugs “pose a greater danger” than those who drink alcohol. In a separate filing for the case, the Justice Department also emphasized that “the question presented is the subject of a multi-sided and growing circuit conflict.” In asking the court to take up the dispute, the solicitor general also noted that the defendant is a joint American and Pakistani citizen with alleged ties to Iranian entities hostile to the U.S., putting him on the FBI’s radar. Meanwhile, the Biden administration was evidently concerned about potential legal liability in federal cases for people convicted of violating gun laws simply by being a cannabis consumer who possessed a firearm, documents obtained by Marijuana Moment show. The previously unpublished 2024 guidance from former President Joe Biden’s Justice Department generally cautioned U.S. attorneys to use discretion in prosecuting federal cannabis cases, particularly for offenses that qualified people for pardons during his term. But one section seems especially relevant as the Supreme Court takes on a case challenging the constitutionality of the current federal gun statute. In interviews with Marijuana Moment, several Republican senators shared their views on the federal ban on gun possession by people who use marijuana—with one saying that if alcohol drinkers can lawfully buy and use firearms, the same standard should apply to cannabis consumers. Sauer, the solicitor general, sent the justices a letter in April arguing that the Trump administration’s move to federally reschedule marijuana should not impact their decision in the Hemani case. The post Congressional Researchers Lay Out Lawmakers’ Options To Address Gun Ban For Marijuana Users Following Supreme Court Ruling appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Two Trump administration cabinet members have announced that their departments are launching a new partnership to collaborate on research and development of psychedelic medicines to treat people struggling with serious mental health conditions. The Department of Health and Human Services (HHS) and Department of Veterans Affairs (VA) signed a memorandum of understanding, unveiled on Monday, that comes months after President Donald Trump issued an executive order aimed at expanding and expediting research on the potential therapeutic benefits of psychedelics. “America owes every veteran the best care our nation can provide,” HHS Secretary Robert F. Kennedy, Jr. said in a press release. “We’re not going to wait while promising treatments sit on the sidelines. Thanks to President Trump’s leadership, HHS and the VA are working together to develop safe, FDA-approved innovations and transition them from research into care so veterans can access the treatments they deserve.” VA Secretary Doug Collins said that “President Trump opened up a world of possibility for treating veterans and others with mental health conditions, and VA is proud to be part of this important work.” “Today’s MOU ensures effective cooperation with HHS as we try to turn research into life-changing treatment,” he said. HISTORIC: Secretary Doug Collins and Secretary Robert F. Kennedy, Jr. have signed an MOU to improve cooperation on psychedelic drug trials between VA and HHS. Read: https://t.co/iSEZ0QtN5q pic.twitter.com/0OLQyHh4yu — Veterans Affairs (@DeptVetAffairs) July 13, 2026 Under the MOU, the two departments will coordinate workforce training, develop clinical protocols and support research and real-world evidence generation. The goal is to prepare VA’s healthcare system to be able to implement any psychedelic medicines that receive Food and Drug Administration (FDA) approval. The press release says HHS and VA will specifically collaborate under the five-year agreement by: Increasing participation in clinical research on promising rapid-acting mental health treatments for veterans Training therapists, nurses, physicians, and other clinicians to safely administer future FDA-approved rapid-acting psychiatric drug products Collecting and sharing real-world data on the safety, effectiveness, and costs of these treatments to improve patient care and inform future policy Coordinating research and sharing evidence as appropriate and consistent with legal authority that may help inform future FDA regulatory decisions and coverage policies Developing clinical guidance and educational resources to help providers — and ultimately patients — understand how approved treatments should be delivered safely and effectively A second MOU announced on Monday between VA and FDA is aimed at bolstering information-sharing and scientific collaboration to advance psychedelic medicine development. “Too many Americans and their families continue to be affected by substance use disorder and serious mental illness, and we have a responsibility to pursue every appropriate opportunity to advance new treatment options,” FDA Acting Commissioner Kyle Diamantas said. “This agreement strengthens collaboration between the FDA and the Department of Veterans Affairs, allowing us to better leverage clinical trial data, real-world evidence, and scientific expertise to help speed the development and review of promising therapies while maintaining our rigorous standards for safety and effectiveness. By working together, we can help deliver new hope to patients who urgently need better treatment options.” Proud to partner with @SecKennedy on accelerating psychedelic medical treatments for Veterans suffering from mental illness. Readhttps://t.co/sgeo7hUtvO pic.twitter.com/pgfGKVOD9l — VA Secretary Doug Collins (@SecVetAffairs) July 13, 2026 Meanwhile, the National Institute on Drug Abuse (NIDA) also announced that it is awarding $2.3 million to support an investigational new drug application for ibogaine. “There is preliminary evidence that psychedelic therapies can rewire the brain and produce rapid improvements for people with serious mental illness or substance use disorders,” National Institutes of Health Director Jay Bhattacharya said. “However, we still have much to learn about long-term benefits and risks, including the potential for misuse. This collaboration helps strengthen the scientific foundation and clinical readiness needed to support safe, effective, real-world implementation.” Additionally, the HHS Advanced Research Projects Agency for Health (ARPA-H) is making available separate funds to support research on ibogaine’s role in treating opioid use disorder. “Treatment for opioid use disorder has been stuck in an innovation rut for decades, and Americans are paying a heartbreaking price,” ARPA-H Director Alicia Jackson said. “ARPA-H is poised to take bold action and knock down barriers to exploring the therapeutic potential of ibogaine for this devastating condition.” Finally, the HHS Health Resources and Services Administration (HRSA) issued a request for information on how the healthcare system should prepare to implement psychedelic medicines. “HRSA is committed to ensuring that health professionals and community-based healthcare providers are prepared to safely and effectively deliver innovative therapies as new options become available for people living with serious mental illness,” HRSA Administrator Tom Engels said. “By seeking input from clinicians, health centers, behavioral health providers, rural health experts, researchers, and other stakeholders, HRSA will be better positioned to understand the workforce training, care delivery models, and operational considerations needed to support the safe implementation of potential FDA-approved psychedelic drug products in the future.” Separately on Monday, FDA issued finalized guidance to help researchers studying the therapeutic benefits of psychedelics navigate the “unique challenges” of such investigations. The agency also announced it will be holding a public hearing on psychedelic therapy issues in September. FDA is taking new steps to support the development of potential psychedelic drug therapies for serious mental health conditions. Today, FDA, issued final guidance for industry on clinical investigations of psychedelic drugs, announced a public hearing to gather stakeholder input… pic.twitter.com/Y102CzYiOi — U.S. FDA (@US_FDA) July 13, 2026 Previously, FDA and HHS in April announced steps that they say will help with “accelerating” therapeutic access to psychedelics for patients dealing with serious mental health conditions. In May, a bipartisan coalition of 32 members of Congress sent a letter urging FDA to expedite ongoing reviews of psychedelic therapies. This month, lawmakers filed a new bill that would require the Department of Defense (DOD) to evaluate how ongoing research on the therapeutic benefits of psilocybin could help members of the military. A separate recently introduced bipartisan measure is intended to codify Trump’s psychedelics executive order into law. A pending proposed amendment to the National Defense Authorization Act would extend a psychedelics research effort at DOD for an additional six years. Image courtesy of CostaPPR. The post Federal Health Officials And VA Launch Psychedelic Research Partnership appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

PA marijuana licensing bill; Congressional bill on cannabis/drug testing in hospitals advances; MA psychedelics vote; Hemp & marijuana op-ed Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The Food and Drug Administration published a finalized version of guidance aimed at helping researchers studying the therapeutic benefits of psychedelics navigate the “unique challenges” of such investigations—and has also scheduled a public hearing on the issue for September. The House Energy and Commerce Subcommittee on Health approved a bill to require the Department of Health and Human Services to study how prevalent drug testing for marijuana, fentanyl and other drugs is in hospital emergency departments. The Massachusetts House of Representatives passed an economic development bill that includes provisions to create a five-year pilot program allowing the use of psychedelics to treat mental health conditions. Pennsylvania representatives filed a bill to award medical marijuana licenses to small, diverse and disadvantaged businesses—with the sponsor saying that the diversity goal included in the program “has not been met due to multistate corporations dominating the Commonwealth’s medical cannabis industry.” Morgan Tweet of IND HEMP argues in a new Marijuana Moment op-ed that cannabis businesses should support a new proposal called the Goodness of Hemp Act that she says addresses the concerns of regulated operators “while creating a framework that prioritizes consumer protection, market accountability and long-term industry stability.” / FEDERAL The U.S. Embassy and Consulate in Thailand sent an alert about new customs policies related to cannabis in the country. Former Sen. Cory Gardner (R-CO) tweeted that the late Sen. Lindsey Graham (R-SC) once told him, “Sorry, Cory. I can’t help Colorado solve its marijuana problem. While y’all got potheads, I got Baptists.” / STATES Nebraska’s attorney general spoke about approval of medical cannabis regulations. A Pennsylvania senator said he doesn’t “currently have the votes to move” his marijuana legalization bill through the committee he chairs. Members of the Puerto Rico Senate Health Committee are inspecting medical cannabis businesses this week. A federal judge rejected hemp farmers’ request for more time to appeal dismissal of their lawsuit challenging Maryland product restrictions. Montana regulators adopted changes to rules on marijuana product recalls. New York regulators launched new resources to help young people and the adults they trust discuss cannabis. Missouri regulators published the latest issue of their marijuana podcast. Oregon regulators will consider a marijuana business stipulated settlement agreement on Thursday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL An Irish senator authored an op-ed about the need to decriminalize drugs. Ghana’s government is considering legalizing industrial hemp. / SCIENCE & HEALTH A study suggested that “cannabidiol may represent a promising complementary therapeutic strategy for reducing orofacial pain associated with temporomandibular disorders.” A review concluded that “CBD is useful for people with epilepsy that doesn’t respond to other treatments.” / ADVOCACY, OPINION & ANALYSIS A Concerned Women for America official authored an op-ed arguing that marijuana should remain in Schedule I. / BUSINESS Ascend Wellness Holdings, Inc. is asking shareholders to approve a reverse stock split in support of a plan to uplist on a major U.S. exchange. Tilray Brands, Inc. is launching medical cannabis products in Panama. Quest Diagnostics published an annual report indicating that positive hair drug tests for marijuana and other substances among the U.S. workforce have increased over the last five years. / CULTURE Wrestler Rob Van Dam said marijuana is a “gateway out” of heroin addiction. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post FDA’s new psychedelic guidance & hearing (Newsletter: July 14, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Compete against skilled players from around the world in 2v2.io and prove your abilities in fast-paced multiplayer team battles every day.

The software says stunning to read these sort of revealing and additionally completely unique articles or reviews upon your webpages. https://joker123-game.co/

Took me time to read all the comments, but I really enjoyed the article. It proved to be Very helpful to me and I am sure to all the commenters here! It’s always nice when you can not only be informed, but also entertained! slot 5k

I found that site very usefull and this survey is very cirious, I ' ve never seen a blog that demand a survey for this actions, very curious... bola online

Butuh teks kosong untuk keperluan copy-paste di media sosial, aplikasi perpesanan, atau pengujian sistem? Anda berada di tempat yang tepat. Layanan kami menyediakan karakter khusus yang tidak terlihat oleh mata manusia namun terbaca oleh sistem sebagai teks, memungkinkan Anda untuk mengirim pesan kosong, membuat nama profil yang tidak terlihat, atau memformat kolom input sesuai kebutuhan Anda.

The Food and Drug Administration (FDA) has issued finalized guidance to help researchers studying the therapeutic benefits of psychedelics navigate the “unique challenges” of such investigations. The agency also announced it will be holding a public hearing on psychedelic therapy issues in September. “In recent years, interest in the therapeutic potential of psychedelic drugs has been increasing,” the FDA document published on Monday says. “Drug development programs for psychedelic drugs are subject to the same regulations and same evidentiary standards for approval as other drug development programs,” the agency wrote. “However, designing clinical studies to evaluate the safety and effectiveness of these products presents a number of unique challenges.” Psychedelics can “cause intense perceptual disturbances and alterations in consciousness that can last for several hours or days,” and can “have both rapid-onset and long-term benefits after only one or a few doses,” FDA said. The guidance—titled “Psychedelic Drugs: Considerations for Clinical Investigations”—notes that psychedelics are an “an emerging area of drug development” and provides considerations that sponsors of research on substances like psilocybin, LSD and MDMA should take into account. Among other areas, FDA is providing recommendations on how psychedelic studies handle issues such as chemistry, manufacturing, abuse potential and clinical pharmacology. It notes that designing well-controlled studies on psychedelics can be particularly challenging due to the “often intense perceptual changes induced by the drugs.” “This increases the potential for bias due to functional unblinding of patients, therapists, monitors, or raters,” the FDA document says. “Functional unblinding can lead to expectation bias in the patients who experience perceptual disturbances, or in those who observe them, which may lead to an expectation that the participant will experience clinical benefit; alternatively, those who receive a placebo and do not experience or observe a perceptual change may expect that the participant will not benefit.” The final guidance builds on a draft version that FDA initially published in 2023 and comes months after President Donald Trump issued an executive order aimed at expanding and expediting research on the potential therapeutic benefits of psychedelics. The agency said it took into account comments received in response to the draft version, and it is also accepting additional public feedback on the final document, FDA said in a Federal Register notice. Meanwhile, FDA on Monday also announced that it will hold a public hearing on September 14 to “obtain feedback and perspectives on issues associated with the potential future therapeutic use of drug products containing a psychedelic drug substance in supervised and supportive settings.” “The hearing will be conducted by a presiding officer, who will be accompanied by FDA panelists, including subject matter experts from the Center for Drug Evaluation and Research, as well as federal partner panelists,” the agency said in a Federal Register notice about the hearing. FDA is inviting interested parties to apply to present about specific topics at the hearing, but it also made clear it is not inviting commentary about certain matters. “FDA and our federal partners are interested in public input on the potential future therapeutic use of psychedelic drugs in supervised and supportive settings, including the following topics: (1) provider training and credentialing, (2) promotion of patient safety, (3) considerations for access, and (4) best practices for data collection and standardization,” it said. “FDA is not seeking comment on the following topics: (1) the safety or effectiveness of any particular drug product, or the merits of any pending or anticipated application before the Agency; (2) the scheduling status of any substance under the Controlled Substances Act, which is addressed through separate statutory processes; (3) the legalization or decriminalization of psychedelic substances, or the merits of state or local programs authorizing their use, although FDA welcomes input on data collection from such programs as described above; (4) religious, ceremonial, or personal (non-medical) use of psychedelic substances; or (5) individual disputes, enforcement matters, or complaints regarding specific practitioners or entities. Comments and presentations addressing these topics may not be considered.” FDA and the Department of Health and Human Services (HHS) in April announced steps that they say will help with “accelerating” therapeutic access to psychedelics for patients dealing with serious mental health conditions. In May, a bipartisan coalition of 32 members of Congress sent a letter urging FDA to expedite ongoing reviews of psychedelic therapies. This month, lawmakers filed a new bill that would require the Department of Defense (DOD) to evaluate how ongoing research on the therapeutic benefits of psilocybin could help members of the military. A separate recently introduced bipartisan measure is intended to codify Trump’s psychedelics executive order into law. A pending proposed amendment to the National Defense Authorization Act would extend a psychedelics research effort at DOD for an additional six years. Photo elements courtesy of carlosemmaskype and Apollo. The post FDA Finalizes Guidance On ‘Unique Challenges’ Of Psychedelic Research And Schedules Hearing On Therapeutic Uses appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I wanted to thank you for this great read!! I definitely enjoying every little bit of it I have you bookmarked to check out new stuff you post. Taruhan Bola Parlay I wanted to thank you for this great read!! I definitely enjoying every little bit of it I have you bookmarked to check out new stuff you post. Situs Taruhan Sports I wanted to thank you for this great read!! I definitely enjoying every little bit of it I have you bookmarked to check out new stuff you post. Domino88 Online I wanted to thank you for this great read!! I definitely enjoying every little bit of it I have you bookmarked to check out new stuff you post. Roulette Online I wanted to thank you for this great read!! I definitely enjoying every little bit of it I have you bookmarked to check out new stuff you post. Bandar Togel I wanted to thank you for this great read!! I definitely enjoying every little bit of it I have you bookmarked to check out new stuff you post. Ilucky88 Slot

“The Goodness of Hemp Act represents one of the most reasonable opportunities for compromise currently on the table.” By Morgan Tweet, IND HEMP Few industries have watched the rise of hemp-derived intoxicating products with more frustration than regulated cannabis. Yet one of the more interesting realities of this debate is that many cannabis operators have quietly entered the hemp market themselves. While publicly advocating for stricter restrictions on hemp-derived products, many have simultaneously launched hemp beverage brands, cannabinoid product lines or other investments tied to the category’s growth. That contradiction reveals something important: this debate is no longer about whether consumer demand exists. It does. The real question is what framework should govern it. One answer may be the Goodness of Hemp Act, a draft legislative framework developed by a coalition of hemp stakeholders and currently being shared with policymakers as Congress debates the future of hemp-derived cannabinoids. Though not yet formally introduced, the proposal is being considered by congressional offices both as a comprehensive framework and as a source of specific provisions that could strengthen existing legislative efforts—offering a path to better balance consumer protection, agricultural interests and long-term market stability. What we are suggesting is simple: regulated cannabis operators should be far more focused on how to responsibly regulate hemp than how to eliminate it. It’s not hard to understand why many in regulated cannabis businesses have placed a target on the hemp industry. After years of competing against products operating under a different set of rules, many operators view the approaching November 12 federal recriminalization of hemp THC products as an opportunity to finally reset the playing field. Some have spent years advocating for stronger restrictions on hemp-derived intoxicating products and may see recent legislative activity as evidence that those efforts are finally paying off. But there is an important question worth asking: What happens next? If the objective is simply to eliminate today’s hemp-derived marketplace, the industry may discover that prohibition solves less than expected. Some consumers will undoubtedly leave the category altogether. Many are not prepared to make the leap from a low-dose hemp beverage or wellness product to becoming a traditional cannabis consumer. The assumption that all of that demand simply migrates into regulated cannabis markets is unlikely to prove true. At the same time, history suggests that demand rarely disappears entirely. Poorly constructed policy often creates opportunities for underground operators willing to ignore the rules altogether. As legitimate businesses exit the market, bad actors are often left to fill the void with lower-quality, untested and potentially unsafe products. When those products reach consumers, they rarely distinguish between hemp, cannabis or cannabinoids. They simply conclude that the category itself cannot be trusted. Every negative consumer experience, every mislabeled product and every irresponsible operator damages confidence not only in hemp-derived products, but in cannabis products as well. The industry has spent years fighting stigma. It should be cautious about creating conditions that reinforce it. That is why efforts to modify or replace the hemp provisions included in last year’s congressional appropriations process should be a serious topic of interest for regulated cannabis operators. Congress has already signaled that the status quo is unlikely to continue. The question is no longer whether change is coming. The question is what replaces it. With Congress expected to revisit hemp policy later this year, the industry has an opportunity to move beyond temporary extensions and begin discussing what a durable national framework could actually look like. We believe the Goodness of Hemp Act represents one of the most reasonable opportunities for compromise currently on the table. Not because it ignores the concerns of regulated cannabis, but because it addresses them directly while creating a framework that prioritizes consumer protection, market accountability and long-term industry stability. First, the draft legislation would restrict inhalable hemp products, addressing one of the primary concerns raised by regulated cannabis operators. By reserving this category for regulated cannabis, the proposal creates greater certainty around market boundaries and reinforces the value of compliance within state-regulated programs. Inhalables remain the core dispensary product category, making this one of the most direct benefits for state-licensed operators. Second, the proposal would create clearer distinctions between hemp and cannabis based on THC concentration and intended use. The result is greater certainty about where hemp begins and ends, where cannabis begins and which regulatory framework applies. Third, and perhaps most importantly, the draft language creates a framework that prioritizes consumer protection and responsible market development over regulatory ambiguity. Instead of allowing bad actors to define the marketplace, it establishes guardrails that help legitimate businesses compete while giving consumers greater confidence in the products they purchase. Millions of consumers are being introduced to cannabinoids through low-dose beverages, wellness products and other regulated formats. Over time, that exposure can reduce stigma, improve understanding and help consumers become more comfortable navigating the broader cannabinoid marketplace. The counterintuitive reality is that the long-term success of regulated cannabis may depend less on eliminating hemp and more on helping shape the rules that govern it. Those rules should establish clear boundaries, reward compliance, protect consumers and build trust across the entire cannabinoid category. And that is where the Goodness of Hemp Act stands apart from many of the proposals currently being debated in Washington, D.C. Most focus on extending timelines, preserving the status quo or addressing a single segment of the market. The Goodness of Hemp Act takes a different approach. It seeks to create a durable framework that puts consumers first, supports farmers, establishes clear guardrails and provides a pathway for long-term market stability. The Goodness of Hemp Act is the product of extensive collaboration among stakeholders who recognized that the industry needs more than another extension, carveout or temporary fix. It represents one of the first serious attempts to develop a long-term framework that could provide greater clarity for regulated operators, stronger protections for consumers and new opportunities for farmers and rural communities. The conversation surrounding hemp has spent years focused on what one industry stands to lose. But the bigger question may be what the entire cannabinoid economy stands to gain from clearer rules and greater certainty. Regulated cannabis operators have legitimate concerns about today’s hemp marketplace. So do farmers, manufacturers, retailers and consumers. The debate has already moved beyond whether change is needed. The question now is what comes next. If lawmakers can create a system that protects consumers, establishes clear boundaries and rewards responsible businesses, both hemp and cannabis could emerge stronger. The future of cannabinoids will not be shaped by the industries that spend the most time fighting one another, but by those willing to do the difficult work of building rules that consumers can trust and legitimate businesses can operate under for years to come. Morgan Tweet is co-founder and CEO of IND HEMP and executive director of The Hemp Feed Coalition. She is helping lead a broad coalition of stakeholders working to align the interests of industrial hemp, consumer cannabinoid products and American agriculture around a comprehensive federal regulatory framework. Photo courtesy of Brendan Cleak. The post Hemp And Marijuana Businesses Should Unite Around A New Regulatory Framework That Protects Consumers And Supports Farmers (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

As Pennsylvania Democrats ramp up pressure to Republicans to allow a vote on marijuana legalization in the state Senate, a group of House members have filed a new bill that would prioritize issuing licenses to small, diverse and disadvantaged businesses through the state’s existing medical cannabis program. The legislation, from Rep. Nathan Davidson (D) and seven cosponsors, would expand the medical marijuana program by adding an additional dispensary permit in each geographic region of the state to a disadvantaged, diverse or small business. It would also require regulators to publish an annual list of surrendered or revoked medical cannabis business licenses and then accept applications from disadvantaged, diverse or small businesses to re-award those licenses. A “disadvantaged business” would be defined under the legislation as being owned or controlled by a majority of people, not limited to members of minority groups, who are subject to racial or ethnic prejudice or cultural bias. A “diverse business” means a disadvantaged business, minority-owned or women-owned business or service-disabled veteran-owned or veteran-owned small business that has been certified by a third party certifying organization. A “small business” under the bill means an independently owned and operated for-profit business that employs 100 or fewer employees and is not a subsidiary or affiliate of a corporation. Davidson wrote in a cosponsorship memo for the bill earlier this year that the diversity goal included in the medical cannabis program “has not been met due to multistate corporations dominating the Commonwealth’s medical cannabis industry.” “Small, diverse, and/or disadvantaged businesses have largely been prevented from competing for dispensary permits,” he said. “To help meet these needs, I am introducing legislation that would require the Department of Health to annually reallocate all surrendered, revoked, or vacated permits to small, diverse, and/or disadvantaged businesses. This legislation will give these businesses the initial opportunity to compete for these permits.” “Please join me in co-sponsoring this important legislation to expand patient access to care and ensure all communities across the Commonwealth are given fair access to medical cannabis products,” Davidson wrote to colleagues. Meanwhile, Senate Democrats recently filed a discharge resolution that seeks to bring a bipartisan cannabis legalization bill out of committee, where it is stuck, and onto the floor for a vote. The legislative maneuvering around the bill comes as new poll shows that Pennsylvania voters overwhelmingly support marijuana legalization—and that the largest share put the blame on Republican lawmakers for the fact that the state has not yet enacted the reform. Gov. Josh Shapiro (D) has repeatedly called on lawmakers to send him a marijuana legalization bill and for the last several years has included the reform in his budget requests to the legislature. Republican gubernatorial nominee Stacy Garrity, who is running against Shapiro, recently pledged to veto a marijuana legalization bill if lawmakers ever sent one to her desk—though she added that she doesn’t think the reform stands a chance of making it that far in the state. “I don’t support legalizing recreational marijuana,” she said. “Recreational marijuana will not end up in the budget. They’re never going to pass it…not as long as Senate Republicans are in control of the Senate.” Her running mate for lieutenant governor, Jason Richey, claimed that legalizing marijuana would be “catastrophic” for the state, arguing it would increase the size of the illegal market, undermine job creation and harm public health. In April, the Democratic-controlled Pennsylvania House of Representatives passed budget legislation proposed by Shapiro that relies on revenue that would be generated from recreational marijuana sales, which has yet to be legalized in the state. The governor earlier this year, as he has in past years, included cannabis legalization and the resulting expected revenue in his budget request. The House last year passed a bill to legalize marijuana and put sales in state-owned dispensaries, but the Republican Senate majority has criticized that plan while also not advancing a cannabis legalization model of its own. The state’s Independent Fiscal Office (IFO) reported in February that legalizing cannabis in Pennsylvania would generate nearly half a billion dollars in annual revenue by 2028, an estimate that is a significantly larger cash windfall compared to projections from Shapiro’s own office. A spokesperson in the governor’s office said the Trump administration’s federal marijuana rescheduling move is an “important step” that “adds support” to his push to legalize cannabis. A GOP senator also said that federal reform will make it easier to legalize marijuana in the state. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, a Republican senator is blaming the governor for the defeat of his bill to create a new Cannabis Control Board (CCB) to oversee the state’s medical marijuana program and intoxicating hemp products and that could also one day oversee recreational cannabis if it is legalized. Most GOP senators in the Republican-controlled chamber voted for the legislation, and all but two Democrats opposed it—with even some lawmakers who signed onto the measure as cosponsors ultimately voting against it. The governor “obviously weighed in on the Democratic side of the aisle and asked for a ‘no’ vote over there, successfully,” Sen. Dan Laughlin (R) said after the vote. “I knew it was a risk putting it up for a vote, because there were some discussions going back and forth… I had a little bit of a heads-up, but we chose to roll forward.” The governor’s office confirmed in a statement that he opposes the bill as drafted. “The Shapiro Administration remains supportive of comprehensive cannabis regulation, which would enable a competitive, revenue-generating adult-use market, protect patient access to the current Medical Marijuana Program and rein in hemp-based intoxicant products that are currently unregulated,” Rosie Lapowsky, a spokesperson for the governor, said. “Senate Bill 49 does not substantively advance those goals.” The now-defeated measure would transfer regulatory authority for the state’s existing medical cannabis program from the Department of Health to a new seven-member CCB. The body would oversee cannabis permits, enforcement, seed-to-sale tracking, advertising, labeling, testing and other aspects of the legal industry. Moments after the bill’s defeat on the Senate floor, the chamber adopted a motion to reconsider—but it’s not yet clear when or if the legislation will get another vote. Laughlin’s legislation would also significantly restrict most hemp THC products, aligning the state with a new federal policy that is set to take effect later this year recriminalizing preparations with total THC content of more than 0.3 percent on a dry-weight basis or more than 0.4 milligrams of THC per container. The action on the cannabis regulatory bill, SB 49, came shortly after the House of Representatives passed a bill to allow terminally ill patients to use medical cannabis in hospitals and other healthcare facilities. The post New Pennsylvania Bill Would Award Medical Marijuana Licenses To Small, Diverse and Disadvantaged Businesses appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A very awesome blog post. We are really grateful for your blog post. You will find a lot of approaches after visiting your post. Situs Dominoqq A very awesome blog post. We are really grateful for your blog post. You will find a lot of approaches after visiting your post. Situs Taruhan Bola A very awesome blog post. We are really grateful for your blog post. You will find a lot of approaches after visiting your post. Slot Online Terpercaya A very awesome blog post. We are really grateful for your blog post. You will find a lot of approaches after visiting your post. Bolagila Resmi A very awesome blog post. We are really grateful for your blog post. You will find a lot of approaches after visiting your post. Situs Livecasino Online A very awesome blog post. We are really grateful for your blog post. You will find a lot of approaches after visiting your post. Agen Sbobet

The Massachusetts House of Representatives has voted to create a five-year pilot program allowing the use of psychedelics to treat mental health conditions. Under the proposal, which is part of a $561 million bond bill that was approved by a vote of 148-2 on Wednesday, “clinically appropriate patients” could use “naturally occurring psychedelic materials” for “on-site administration by a multi-disciplinary care team in a supervised licensed mental health clinic setting.” Under the legislation, there would be a new Medical Psychedelics Fund, and the Department of Public Health would issue up to three permits to mental health clinics to participate in the program “for the purposes of establishing the best and safest clinical practices for psychedelic mental health treatment programs” and for the purposes of “collecting patient outcomes data regarding the benefits of psychedelic pharmacotherapy.” Participating clinics could not be “subsidiaries, affiliates or members of cannabis industry organizations, psychedelic molecule development companies or pharmaceutical companies,” it says, and they would need to “track patient care outcomes data related to the identification, diagnosis and psychedelic treatment of depression, anxiety, post-traumatic stress disorder and substance use disorder.” The measure specifies that current state drug criminalization laws “shall not apply to the medical use of psilocybin and psilocin as provided under the pilot program.” With respect to other psychedelics, the legislation says that state health officials will “coordinate with research institutions, as it deems appropriate, to facilitate, expand and expedite federally-authorized research on psychedelic-assisted therapies, including, but not limited to, psilocybin, ibogaine, 5-methoxy-n,n-dimethyltryptamine, and 3,4-methylenedioxymethamphetamine, in the commonwealth, including efforts to pursue federal approvals and available state and federal funding in compliance with applicable federal regulations.” The department would be charged with issuing regulations to oversee the effort, including on the “process of storing, dispensing and administrating psychedelics.” “The department shall establish by regulation all standards and requirements governing the production and cultivation of naturally occurring psychedelic materials necessary for the pilot program, including, but not limited to, producer licensing and operations,” the bill says. The psychedelics reform was championed by Rep. Marjorie Decker (D) and was folded into a larger amendment that was adopted to the bill in a unanimous vote. The House-passed economic development bill next heads to the Senate and then, potentially, to the desk of Gov. Maura Healey (D). — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — “It’s pretty mind-blowing to see that psychedelics offer, under the right medical guidance, real treatment, and I want to be bold to say it cures,” Decker told The Boston Globe. “It’s not a lifetime of treatment. It’s a cure.” “It’s great to see that there’s an alignment in which the federal government and state government is moving in the same direction of trying to make people’s lives better,” she said, referring to a psychedelics executive order President Donald Trump signed in April. “But we certainly have not been a state…that has been waiting for the winds of change at the federal level to decide how to take care of people in our state.” The passage of the psychedelics legislation comes after Massachusetts voters in 2024 defeated a ballot measure that would have broadly legalized psychedelics, allowing adults 21 and older to legally possess, grow and share certain amounts of substances such as psilocybin, ibogaine and DMT. Advocates praised the new legislative development. “This is a triumph for a new kind of politics in the psychedelics movement, built on integrity, compromise and mutual, earned trust among grassroots advocates, lawmakers, scientific researchers, national organizations and philanthropists,” Graham Moore, educational outreach director for Mass Healing, said in a press release. “At the beginning of this legislative session, the psychedelic movement was operating with a trust deficit in Massachusetts because of catastrophic mismanagement. This victory was possible only through responsible leadership: unafraid to confront bad actors, admit mistakes, and operate dynamically.” Jamie Morey, the group’s executive director, said that the group was “born from the ashes of the failed 2024 psychedelic ballot question and fueled by my passion as a mother on a mission to keep fighting for legal access to psychedelic healing for my own family and others across Massachusetts. “The House’s passage of this bill is a victory for everyone affected by PTSD, treatment-resistant depression, addiction and other serious mental and physical health conditions who urgently need new treatment options,” she said. During the current legislative session, various pieces of psychedelics legislation have been filed, with some clearing committees. The Massachusetts Psychiatric Society endorsed several of the psychedelics reform bills, including one to decriminalize psilocybin possession. In 2024, the governor signed a military veterans-focused bill that includes provisions to create a psychedelics working group to study and make recommendations about the potential therapeutic benefits of substances like psilocybin and MDMA. Meanwhile in Massachusetts, state officials have formally certified that an initiative to roll back that state’s marijuana legalization law will appear on the November ballot. The anti-cannabis campaign, however, is facing a new challenge to some of its most recently submitted signatures. The post Massachusetts Lawmakers Pass Bill To Legalize Psychedelic Therapy With New Pilot Program appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A congressional committee has advanced legislation that would require the Department of Health and Human Services (HHS) to study how prevalent drug testing for marijuana, fentanyl and other drugs is in hospital emergency departments. The House Energy and Commerce Subcommittee on Health last month approved the legislation from Rep. Ted Lieu (D-CA), known as “Tyler’s Law,” after Tyler Shamash, a 19-year-old who died following a fentanyl ingestion in 2018 and was not tested for the drug when brought to the hospital for a suspected overdose. While the legislation, H.R. 2004, is largely focused on fentanyl, it says that within a year of passage the HHS secretary would need to complete a study to determine “how frequently hospital emergency departments test for fentanyl (in addition to testing for other substances such as amphetamines, phencyclidine, cocaine, opiates, and marijuana) when a patient is experiencing an overdose.” The study would also need to look at costs associated with fentanyl testing, the potential benefits and risks of such testing and how it may impact patients’ experiences—including with respect to confidentiality and privacy protections and the patient-physician relationship. The bill, which has 60 House cosponsors, says that within six months of completing the study, HHS would also need to issue guidance covering: “(1) Whether hospital emergency departments should implement fentanyl testing as a routine procedure for patients experiencing an overdose. (2) How hospitals can ensure that clinicians in their hospital emergency departments are aware of which substances are being tested for in their routinely-administered drug tests, regardless of whether those tests screen for fentanyl. (3) How the administration of fentanyl testing in hospital emergency departments may affect the future risk of overdose and general health outcomes.” The House committee approved the bill without amendment in a voice vote. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Companion legislation in the Senate from Sen. Jim Banks (R-IN) was approved by the Health, Education, Labor, and Pensions Committee in January—but not before being amended to remove the language that references marijuana and other drugs besides fentanyl. Unlike the House bill, the HHS secretary would have three years to complete the study on hospital drug testing under the amended Senate proposal. In April, a pair of Republican senators filed a separate bill that would require the federal government to track the cost of hospitalization due to marijuana use. The Marijuana Impact on Medicaid Act of 2026 from Sens. Ted Budd (R-NC) and Pete Ricketts (R-NE) would require the secretary of the Department of Health and Human Services (HHS) to compile data on “Federal and State expenditures under the Medicaid program…that are attributable to costs incurred for providing medical assistance for inpatient hospital services, outpatient hospital services, and for services received at a hospital emergency room…related to marijuana use.” The bill’s language is similar to two amendments Budd previously filed on the cannabis and hospitalization issue that didn’t end up being considered on the Senate floor. The post Bill To Require Federal Health Officials To Track Testing For Marijuana And Other Drugs In Hospital ERs Advances In Congress appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The web is actually bogged lower along with phony weblogs without any actual information however the publish had been wonderful as well as really worth the actual study. Thanks with regard to discussing this particular beside me. sbobet

GOP congressman: Marijuana makes you a “loser in life”; MA anti-cannabis measure faces challenge; Study: Medical marijuana for restless legs syndrome Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Before you dig into today’s cannabis news, I wanted you to know you can keep this resource free and published daily by subscribing to Marijuana Moment on Patreon. We’re a small independent publication diving deep into the cannabis world and rely on readers like you to keep going. Join us at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Former Acting Homeland Security Secretary Chad Wolf sent a letter urging Congress not to reverse the scheduled recriminalization of hemp THC products, saying it would “embolden foreign criminal actors” linked to China and would “undermine public health.” Rep. Pete Sessions (R-TX) claimed that marijuana “hurts your DNA,” will “make you a loser in life” and leads to young women being “taken advantage of.” “There is not one positive effect of this marijuana.” The Massachusetts State Ballot Law Commission is considering a new challenge to signatures for an initiative to roll back the state’s marijuana legalization law that other state officials certified to appear on the November ballot this week. A study found that medical cannabis is “effective” in reducing the severity of restless legs syndrome. “Improvements were observed after 1 and 3 months of treatment and were maintained after 1 year among patients who continued therapy.” A federal judge on the U.S. Court of Appeals for the Fourth Circuit issued a concurring opinion in a gun case saying that the presumed link between cannabis and firearms “can no longer hold water in this era of widespread marijuana legalization.” Minnesota Psychedelic Medicine Task Force Chair Jessica Nielson describes in a new op-ed how the state is on the verge of making psilocybin therapy available to patients who need it. “The question of whether to create a psilocybin therapeutic access program is not about if, but how it will be implemented.” / FEDERAL Sen. John Fetterman (D-PA) discussed his support for legalizing marijuana and psychedelics. / STATES New Jersey Gov. Mikie Sherrill (D) signed budget legislation that allocates about $82 million in marijuana revenue to various programs. Kansas Republican gubernatorial candidates agreed on opposing marijuana legalization during a debate. Virginia current and former lawmakers continued to clash over accusations that budget legislation with provisions to legalize recreational marijuana sales inadvertently removed all cannabis penalties for a period of a year—though commonwealth’s attorneys who had initially expressed concerns about the issue say that actions taken by the Code Commission solved the problem. Ohio lawmakers are considering legislation to allow single-license marijuana processors to apply for cultivator and dispensary permits. Maryland regulators launched an initiative to connect social equity cannabis businesses with certified minority-owned suppliers. Massachusetts regulators approved a stipulated agreement with a marijuana business over alleged violations. Colorado marijuana regulators published a new dashboard that tracks open records requests. New York’s health commissioner spoke on a panel about recent trends in emergency department visits related to cannabis use. The Georgia Access to Medical Cannabis Commission will meet on Wednesday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL Osseo, Minnesota hosted a town hall meeting about plans to open a municipal-owned marijuana dispensary. / INTERNATIONAL Gandaki, Nepal lawmakers approved a bill to legalize cannabis cultivation for medical and industrial use. Victoria, British Columbia, Canada’s mayor sent a letter to provincial officials in support of a cannabis club. / SCIENCE & HEALTH A study found that “cannabidiol alleviates traumatic brain injury-induced neuronal damage and cognitive deficits.” A study of rats highlighted the “preventive effects of CBD- and THC-containing [cannabis oil] against early liver alterations associated with” metabolic dysfunction-associated steatotic liver disease. / ADVOCACY, OPINION & ANALYSIS The Wall Street Journal editorial board noted California’s ongoing struggles to combat the illicit cannabis market under legalization. The Niskasen Center published a report with recommendations on “building and fixing adult-use cannabis markets.” / BUSINESS Curaleaf Holdings, Inc. announced that exchange-traded options on its subordinate voting shares will commence trading on the Montréal Exchange on Monday. Trulieve Cannabis Corp. was included on TIME’s list of America’s Best Companies 2026. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Former Trump official pushes hemp THC ban (Newsletter: July 13, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Yes, I am entirely agreed with this article, and I just want say that this article is very helpful and enlightening. I also have some precious piece of concerned info !!!!!!Thanks. situs slot resmi

This particular is usually apparently essential and moreover outstanding truth along with for sure fair-minded and moreover admittedly useful My business is looking to find in advance designed for this specific useful stuffs… วิธีแทงบอลสเต็ปสำหรับมือใหม่

Wow i can say that this is another great article as expected of this blog.Bookmarked this site.. kokitoto daftar

Thank you for very usefull information.. game premium oma55

The best horror survival game ever made is FNAF; how about we play it? Discover the terrifying Five Nights at Freddy's with its unsettling shifts and face-moving animatronics right now!

You can drift in Drift Boss for a long time, and the game tests your speed and ability to drive through difficult tracks. Everyone can enjoy the game. You can try to beat your high score, get coins, or open up new cars. There is something new to learn every time you play.

If you want to dive into a brilliant galaxy of quick actions and great smiles, Space Waves is a game that you can play online for free. Maintain a straight line while guiding a bright arrow through neon tunnels using a control that is simple and only requires one button. Every single run is quick, fair, and enjoyable thanks to the game's 33 colourful stages and immediate restarts. Is you prepared to surf the wave?